Adherence of Beta Thalassemia Patients to Oral Chelation Therapy

What this Trial Is About

Beta-thalassemias are inherited blood disorders causing chronic anemia due to problems with hemoglobin production. The severity varies, influencing the need for regular blood transfusions. This research focuses on patients with beta-thalassemia, especially those dependent on transfusions, and evaluates their adherence to oral iron chelation therapy, which is crucial for managing iron overload. The study is sponsored by Sohag University and aims to understand treatment compliance in children and adolescents aged 2 to 18 years. Participants in this study are patients with beta-thalassemia major or intermedia who have been receiving regular blood transfusions every 2 to 5 weeks. They are prescribed oral iron chelation therapy using deferasirox, which they must have taken for at least one year before joining the study. The study follows these patients over one year to monitor their serum ferritin levels, a marker of iron in the body, to assess adherence to the oral treatment. During the study, participants will have their ferritin levels regularly checked to monitor how well they follow the oral therapy. Researchers will also observe any side effects or complications related to the treatment. The total participation period is one year, during which the patient’s iron levels and overall management will be closely reviewed to better understand real-world adherence to oral chelation therapy in this population.

Adherence of Beta Thalssemia Patients to Oral Chelation Therapy